Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.32
GILD's Cash to Debt is ranked higher than
50% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. GILD: 0.32 )
GILD' s 10-Year Cash to Debt Range
Min: 0.23   Max: 3021.78
Current: 0.32

0.23
3021.78
Equity to Asset 0.51
GILD's Equity to Asset is ranked higher than
62% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GILD: 0.51 )
GILD' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.94
Current: 0.51

0.39
0.94
Interest Coverage 14.74
GILD's Interest Coverage is ranked higher than
52% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 14.74 )
GILD' s 10-Year Interest Coverage Range
Min: 5.85   Max: 2509.2
Current: 14.74

5.85
2509.2
F-Score: 4
Z-Score: 6.98
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 40.39
GILD's Operating margin (%) is ranked higher than
97% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. GILD: 40.39 )
GILD' s 10-Year Operating margin (%) Range
Min: -1185.19   Max: 54.68
Current: 40.39

-1185.19
54.68
Net-margin (%) 27.45
GILD's Net-margin (%) is ranked higher than
95% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. GILD: 27.45 )
GILD' s 10-Year Net-margin (%) Range
Min: -1014.81   Max: 40.13
Current: 27.45

-1014.81
40.13
ROE (%) 27.05
GILD's ROE (%) is ranked higher than
97% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. GILD: 27.05 )
GILD' s 10-Year ROE (%) Range
Min: -65.54   Max: 49.48
Current: 27.05

-65.54
49.48
ROA (%) 13.67
GILD's ROA (%) is ranked higher than
96% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. GILD: 13.67 )
GILD' s 10-Year ROA (%) Range
Min: -30.57   Max: 28.53
Current: 13.67

-30.57
28.53
ROC (Joel Greenblatt) (%) 168.81
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. GILD: 168.81 )
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -110.61   Max: 179.23
Current: 168.81

-110.61
179.23
Revenue Growth (%) 13.30
GILD's Revenue Growth (%) is ranked higher than
85% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. GILD: 13.30 )
GILD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 122.4
Current: 13.3

0
122.4
EBITDA Growth (%) 5.40
GILD's EBITDA Growth (%) is ranked higher than
85% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. GILD: 5.40 )
GILD' s 10-Year EBITDA Growth (%) Range
Min: -20.6   Max: 119
Current: 5.4

-20.6
119
EPS Growth (%) 2.90
GILD's EPS Growth (%) is ranked higher than
83% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. GILD: 2.90 )
GILD' s 10-Year EPS Growth (%) Range
Min: -20.6   Max: 153.3
Current: 2.9

-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

GILD Guru Trades in Q1 2013

Louis Moore Bacon 300,000 sh (New)
Mario Gabelli 27,200 sh (+119.89%)
Jeremy Grantham 2,353,984 sh (+29.04%)
Pioneer Investments 1,155,445 sh (+1.51%)
John Rogers 12,056 sh (unchged)
Mariko Gordon 11,570 sh (unchged)
John Griffin 8,000,000 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
John Burbank Sold Out
George Soros Sold Out
David Rolfe 2,251,933 sh (-3.03%)
Vanguard Health Care Fund 6,721,600 sh (-3.48%)
John Hussman 558,000 sh (-20.29%)
RS Investment Management 227,840 sh (-30.92%)
Steven Cohen 244,861 sh (-61.18%)
Joel Greenblatt 9,784 sh (-70.85%)
» More
Q2 2013

GILD Guru Trades in Q2 2013

Paul Tudor Jones 9,200 sh (New)
Jim Simons 196,248 sh (New)
Caxton Associates 125,000 sh (New)
Julian Robertson 387,000 sh (New)
George Soros 125,000 sh (New)
Andreas Halvorsen 929,539 sh (New)
Ken Fisher 1,037,368 sh (New)
Ronald Muhlenkamp 186,525 sh (New)
Steven Cohen 2,311,133 sh (+843.86%)
Pioneer Investments 1,687,369 sh (+46.04%)
David Rolfe 2,459,512 sh (+9.22%)
Jeremy Grantham 2,530,605 sh (+7.5%)
Stanley Druckenmiller 610,700 sh (+1.78%)
Louis Moore Bacon 300,000 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Daniel Loeb 128,000 sh (unchged)
Vanguard Health Care Fund 6,721,600 sh (unchged)
Louis Moore Bacon 150,000 sh (unchged)
John Rogers 12,056 sh (unchged)
Joel Greenblatt Sold Out
Mariko Gordon 10,851 sh (-6.21%)
RS Investment Management 193,680 sh (-14.99%)
Mario Gabelli 21,800 sh (-19.85%)
John Hussman 350,000 sh (-37.28%)
John Griffin 2,950,000 sh (-63.13%)
» More
Q3 2013

GILD Guru Trades in Q3 2013

Daniel Loeb 500,000 sh (New)
John Rogers 65,265 sh (+441.35%)
Caxton Associates 250,000 sh (+100%)
Mariko Gordon 15,934 sh (+46.84%)
Mario Gabelli 31,305 sh (+43.6%)
Jeremy Grantham 2,922,399 sh (+15.48%)
David Rolfe 2,513,914 sh (+2.21%)
Pioneer Investments 1,695,845 sh (+0.5%)
Ronald Muhlenkamp 187,380 sh (+0.46%)
Jean-Marie Eveillard 400 sh (unchged)
Stanley Druckenmiller 610,700 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Andreas Halvorsen Sold Out
RS Investment Management 190,480 sh (-1.65%)
Vanguard Health Care Fund 6,487,800 sh (-3.48%)
Ken Fisher 977,358 sh (-5.78%)
John Hussman 250,000 sh (-28.57%)
John Griffin 1,950,000 sh (-33.9%)
Julian Robertson 254,300 sh (-34.29%)
George Soros 25,000 sh (-80%)
Steven Cohen 49,332 sh (-97.87%)
» More
Q4 2013

GILD Guru Trades in Q4 2013

Louis Moore Bacon 300,000 sh (New)
Paul Tudor Jones 7,997 sh (New)
Ray Dalio 38,621 sh (New)
John Rogers 324,302 sh (+396.9%)
Daniel Loeb 1,500,000 sh (+200%)
Pioneer Investments 2,884,918 sh (+70.12%)
Steven Cohen 63,000 sh (+27.71%)
Julian Robertson 320,001 sh (+25.84%)
Jeremy Grantham 3,386,737 sh (+15.89%)
Mario Gabelli 33,605 sh (+7.35%)
Ken Fisher 1,010,705 sh (+3.41%)
Ronald Muhlenkamp 192,795 sh (+2.89%)
Jean-Marie Eveillard 400 sh (unchged)
Stanley Druckenmiller 610,700 sh (unchged)
George Soros Sold Out
John Hussman Sold Out
Caxton Associates Sold Out
Mariko Gordon 15,452 sh (-3.02%)
RS Investment Management 162,480 sh (-14.7%)
David Rolfe 1,800,984 sh (-28.36%)
Vanguard Health Care Fund 4,630,700 sh (-28.62%)
John Griffin 620,000 sh (-68.21%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2013-12-31 Add 25.84%1.52%$58.9 - $75.2 $ 700%320001
Daniel Loeb 2013-12-31 Add 200%1.27%$58.9 - $75.2 $ 700%1500000
John Griffin 2013-12-31 Reduce -68.21%1.02%$58.9 - $75.2 $ 700%620000
John Hussman 2013-12-31 Sold Out 0.86%$58.9 - $75.2 $ 700%0
Vanguard Health Care Fund 2013-12-31 Reduce -28.62%0.4%$58.9 - $75.2 $ 700%4630700
Ray Dalio 2013-12-31 New Buy0.02%$58.9 - $75.2 $ 700%38621
George Soros 2013-12-31 Sold Out 0.02%$58.9 - $75.2 $ 700%0
Julian Robertson 2013-09-30 Reduce -34.29%0.86%$51.98 - $64.32 $ 7017%254300
Daniel Loeb 2013-09-30 New Buy0.79%$51.98 - $64.32 $ 7017%500000
John Griffin 2013-09-30 Reduce -33.9%0.61%$51.98 - $64.32 $ 7017%1950000
John Hussman 2013-09-30 Reduce -28.57%0.23%$51.98 - $64.32 $ 7017%250000
George Soros 2013-09-30 Reduce -80%0.06%$51.98 - $64.32 $ 7017%25000
Mariko Gordon 2013-09-30 Add 46.84%0.01%$51.98 - $64.32 $ 7017%15934
Mario Gabelli 2013-09-30 Add 43.6%$51.98 - $64.32 $ 7017%31305
John Griffin 2013-06-30 Reduce -63.13%3.09%$47.2 - $56.47 $ 7034%2950000
Julian Robertson 2013-06-30 New Buy2.5%$47.2 - $56.47 $ 7034%387000
Ronald Muhlenkamp 2013-06-30 New Buy2%$47.2 - $56.47 $ 7034%186525
John Hussman 2013-06-30 Reduce -37.28%0.37%$47.2 - $56.47 $ 7034%350000
George Soros 2013-06-30 New Buy0.07%$47.2 - $56.47 $ 7034%125000
Joel Greenblatt 2013-06-30 Sold Out 0.02%$47.2 - $56.47 $ 7034%0
John Burbank 2013-03-31 Sold Out 0.3%$36.725 - $48.94 $ 7068%0
John Hussman 2013-03-31 Reduce -20.29%0.14%$36.725 - $48.94 $ 7068%558000
Joel Greenblatt 2013-03-31 Reduce -70.85%0.05%$36.725 - $48.94 $ 7068%9784
George Soros 2013-03-31 Sold Out 0.02%$36.725 - $48.94 $ 7068%0
Mario Gabelli 2013-03-31 Add 119.89%$36.725 - $48.94 $ 7068%27200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Gilead Sciences Inc

Wedgewood Partners' David Rolfe Comments on Gilead Sciences - Nov 12, 2012

Gilead Sciences (GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter.

From Wedgewood Partners Third Quarter 2012 Review and Outlook.


Check out David Rolfe latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Weekly CFO Sells Highlight: Gilead Sciences Inc., Micron Technology Inc., Adobe Systems Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Gilead Sciences Inc., Micron Technology Inc. and Adobe Systems Inc. Read more...
Health Care Stocks Gurus Investors Are Buying Ahead of Obamacare
Signed into law by President Obama on March 23, 2010, the Affordable Care Act is now headed quickly toward some important dates. The first is Oct. 1, when the Health Insurance Marketplace, a new portal for Americans to shop for health insurance, opens. Then, on Jan. 1, 2014, coverage for those who signed up for a plan in the marketplace begins. Read more...
Wedgewood Partners Trims High Gainers
As the CFA and CIO of Wedgewood Partners Inc., Guru David Rolfe has been managing Wedgewood's portfolio for over 18 years. Rolfe recently increased his position with 18 companies in the first quarter of 2013, but he didn’t buy any new stocks and traded very little otherwise. He did reduce his position with two high-gainers, Gilead Sciences Inc. (GILD), up 126% over the last 12 months and Charles Schwab Corp. (SCHW), up 67% over 12 months. Rolfe’s recently updated portfolio lists 22 stocks, with a total value of $2.98 billion and a quarter-over-quarter turnover of 22%. According to GuruFocus research, Guru David Rolfe made the following trades in the first quarter of 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.30
GILD's P/E(ttm) is ranked higher than
57% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. GILD: 38.30 )
GILD' s 10-Year P/E(ttm) Range
Min: 9.69   Max: 45.97
Current: 38.3

9.69
45.97
P/B 9.20
GILD's P/B is ranked lower than
58% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. GILD: 9.20 )
GILD' s 10-Year P/B Range
Min: 4.16   Max: 42.63
Current: 9.2

4.16
42.63
P/S 10.60
GILD's P/S is ranked higher than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. GILD: 10.60 )
GILD' s 10-Year P/S Range
Min: 3.71   Max: 21.31
Current: 10.6

3.71
21.31
PFCF 40.60
GILD's PFCF is ranked higher than
50% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. GILD: 40.60 )
GILD' s 10-Year PFCF Range
Min: 9.31   Max: 279.8
Current: 40.6

9.31
279.8
EV-to-EBIT 26.30
GILD's EV-to-EBIT is ranked higher than
50% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. GILD: 26.30 )
GILD' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 471.7
Current: 26.3

6.9
471.7
PEG 4.80
GILD's PEG is ranked lower than
57% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. GILD: 4.80 )
GILD' s 10-Year PEG Range
Min: 0.48   Max: 7.1
Current: 4.8

0.48
7.1
Shiller P/E 44.70
GILD's Shiller P/E is ranked higher than
60% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. GILD: 44.70 )
GILD' s 10-Year Shiller P/E Range
Min: 17.87   Max: 1840.8
Current: 44.7

17.87
1840.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.40
GILD's Price/DCF (Projected) is ranked higher than
74% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. GILD: 2.40 )
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 20.81
Current: 2.4

0.77
20.81
Price/Median PS Value 1.10
GILD's Price/Median PS Value is ranked higher than
64% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GILD: 1.10 )
GILD' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 3.91
Current: 1.1

0.37
3.91
Price/Peter Lynch Fair Value 4.30
GILD's Price/Peter Lynch Fair Value is ranked lower than
60% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. GILD: 4.30 )
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.43   Max: 9.13
Current: 4.3

0.43
9.13
Earnings Yield (Greenblatt) 3.80
GILD's Earnings Yield (Greenblatt) is ranked higher than
58% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GILD: 3.80 )
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 14.5
Current: 3.8

0.2
14.5
Forward Rate of Return (Yacktman) 10.71
GILD's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. GILD: 10.71 )
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: 43.5
Current: 10.71

-0.9
43.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GIS.Germany
Gilead Sciences, Inc. was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by docto

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide